Comment from Plasma Protein Therapeutics Association

Summary: The Plasma Protein Therapeutics Association (PPTA) supports the draft guidance on responding to FDA Form 483 observations, noting its value in providing clarity to manufacturers. However, they request specific clarifications regarding how manufacturers should handle "discussion items" that are not formal observations, seeking assurance that voluntary remediation of these items will not be treated as an admission of a CGMP violation.